Franco Moro, CEO & COO – Stevanato Group
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
Address: Viale Shakespeare, 47 – 00144 Rome,Italy
Tel: +39.06.592.64.43
Sigma-tau is a leading Italian pharmaceutical group, established in 1957 that counts today 2432 employees worldwide amongst whom about 400 researchers. It reached a turnover of 605 million euros in 2008.
The headquarters of the group are in Pomezia, and Sermoneta – in the province of Latina- has active installations Biosint for the production of pharmaceutical raw materials, of L-carnitine and its derivatives.
In 2001 was established BiofuturaPharma, based in Milan, that aims to develop pharmaceuticals for the treatment of diseases of the central nervous system and respiratory system. Recently the business has extended to the development and commercialization of products derived from the biological system of carnitine.
Sigma-Tau works through the National Organization for Rare Disorders (NORD) to provide patient assistance programs to help ensure that patients who are underinsured or otherwise financially limited receive their products at little or no cost.
Always investing in research, 16% of turnover in 2008, Sigma-tau aims to continue its development by:
* Increasing commitment to research in biopharma
* Continuous technological upgrading of production systems
* High-quality products
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
CAI is an engineering service company. Its regional manager for South Europe, Andrea Castiglioni, comments on the pharma industry’s need for commissioning and qualification services when looking to reduce time…
Merck Italia’s Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck’s aim to strengthen its position in oncology and the challenges…
Over the past decade, the birth rate in Italy has consistently decreased, making it one of the countries with the lowest birth rates in the world but also one of…
Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic…
Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the…
Ferring Pharmaceuticals’ Federico Gomes de Freitas, General Manager Italy, gives us an overview of how the Italian affiliate fits into the company’s global strategy, especially with respect to reproductive health,…
Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous…
Giorgio Palú, President of the Italian Medicines Agency (AIFA) helps us understand how the agency works, explains the criteria they use to evaluate innovative medicines and tells us about AIFA’s…
Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market. …
SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug…
Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy…
See our Cookie Privacy Policy Here
